Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?

McKesson (MCK) is significantly outperforming its medical peers, with a year-to-date gain of 27.9% compared to the Medical group's average loss of 4.9%; this is further supported by a Zacks Rank of #2 (Buy) and a 1.5% increase in the Zacks Consensus Estimate for full-year earnings over the past quarter, signaling positive analyst sentiment. Benitec Biopharma Limited (BNTC) is another medical stock outperforming the sector, with an 18.3% year-to-date return and a 19.7% increase in current year EPS estimates.

Analysis

McKesson Corporation (MCK) has demonstrated significant outperformance within the Medical sector this year, achieving a year-to-date gain of approximately 27.9%, which starkly contrasts with the Medical group's average loss of 4.9% and the 0.9% loss experienced by its specific Medical - Dental Supplies industry. This robust stock performance is supported by positive analyst sentiment, evidenced by McKesson's current Zacks Rank of #2 (Buy) and a 1.5% upward revision in the Zacks Consensus Estimate for its full-year earnings over the past quarter, indicating an improving earnings outlook. Similarly, Benitec Biopharma Limited (BNTC) has also outpaced the broader Medical sector, delivering an 18.3% year-to-date return. Benitec's favorable outlook is further highlighted by a significant 19.7% increase in its consensus estimate for current year EPS over the last three months and a Zacks Rank of #2 (Buy), despite its Medical - Biomedical and Genetics industry declining by 4.8% year-to-date. Both companies are thus exhibiting strong relative strength and positive earnings estimate trends, positioning them as noteworthy performers in a generally underperforming Medical sector.

Key Decisions for Investors

• Given McKesson's substantial year-to-date outperformance, positive earnings estimate revisions, and #2 (Buy) Zacks Rank, investors might consider it a candidate for continued strength within the Medical - Dental Supplies industry.
• Benitec Biopharma's similar pattern of sector outperformance, marked by a significant upward revision in EPS estimates and a #2 (Buy) Zacks Rank, suggests it warrants close monitoring for potential sustained momentum in the Medical - Biomedical and Genetics space.
• Investors should continue to track earnings estimate revisions and relative performance for both MCK and BNTC, as these are key indicators highlighted for their outperformance within the next one to three months.